文献速递血栓与止血

西罗莫司联合泼尼松龙对比西罗莫司单药治疗卡波西形血管内皮瘤:一项随机临床试验

Sirolimus plus prednisolone vs sirolimus monotherapy for kaposiform hemangioendothelioma: a randomized clinical trial.
PubMed 文献 · Blood · 2022-01-01

本研究在迄今最大队列中比较西罗莫司联合泼尼松龙与西罗莫司单药治疗伴卡梅现象(KMP)的卡波西形血管内皮瘤(KHE)的疗效与安全性。第4周时,联合组37例中35例达到持久血小板反应,单药组36例中24例达到(差异27.9%;95%CI 10.0-44.7)。联合组在初始3周内各时间点持久血小板反应、第1至4周中位血小板计数、第4周纤维蛋白原稳定及第12个月客观病灶反应方面均优于单药组。

要点

  • 第4周持久血小板反应:联合组35/37 vs 单药组24/36,差异27.9%(95%CI 10.0-44.7)。
  • 联合组在初始3周各时间点持久血小板反应、第1至4周中位血小板计数均优于单药组。
  • 联合组第4周纤维蛋白原稳定患者数及第12个月客观病灶反应优于单药组。

核心结论

  • 伴KMP的KHE患者中观察到的反应深刻且令人鼓舞,提示西罗莫司联合泼尼松龙应被视为伴KMP的KHE的有效治疗。

研究设计与样本

  • 随机临床试验,纳入伴KMP的KHE患者,随机接受西罗莫司联合短程泼尼松龙或西罗莫司单药治疗至少12个月,初始治疗后2年完成疗效评估。
  • 该试验在www.clinicaltrials.gov注册,注册号为#NCT03188068。

主要发现

  • 第4周持久血小板反应(血小板计数>100×10^9/L):联合组35/37 vs 单药组24/36,差异27.9%(95%CI 10.0-44.7)。
  • 联合组在初始3周治疗期间各时间点持久血小板反应、第1至4周中位血小板计数、第4周纤维蛋白原稳定患者数及第12个月客观病灶反应均优于单药组。
  • 联合组输血次数少于单药组,疾病后遗症总发生率低于单药组。
  • 治疗期间总不良事件及3-4级不良事件频率两组相似。

关键数值与推荐

  • 主要结局定义为第4周达到持久血小板反应(血小板计数>100×10^9/L)。
  • 治疗至少12个月,初始治疗后2年完成疗效评估。

临床怎么用

  • 作者认为,伴KMP的KHE患者中观察到的反应深刻且令人鼓舞,提示西罗莫司联合泼尼松龙应被视为伴KMP的KHE的有效治疗。

局限性

  • 原文未报告局限性

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

The Kasabach-Merritt phenomenon (KMP) in kaposiform hemangioendothelioma (KHE) is characterized by life-threatening thrombocytopenia and consumptive coagulopathy. This study compared the efficacy and safety of sirolimus plus prednisolone vs sirolimus monotherapy as treatment strategies for KHE with KMP in the largest cohort to date. Participants were randomized to receive either sirolimus in combination with a short course of prednisolone or sirolimus monotherapy for at least 12 months. The primary outcome was defined as achievement of a durable platelet response (platelet count >100 × 109/L) at week 4. Participants completed efficacy assessments 2 years after the initial treatment. At week 4, a durable platelet response was achieved by 35 of 37 patients given sirolimus and prednisolone compared with 24 of 36 patients given sirolimus monotherapy (difference 27.9%; 95% confidence interval, 10.0-44.7). Compared with the sirolimus monotherapy group, the combination treatment group showed improvements in terms of measures of durable platelet responses at all points during the initial 3-week treatment period, median platelet counts during weeks 1 to 4, increased numbers of patients achieving fibrinogen stabilization at week 4, and objective lesion responses at month 12. Patients receiving combination therapy had fewer blood transfusions and a lower total incidence of disease sequelae than patients receiving sirolimus alone. The frequencies of total adverse events and grade 3-4 adverse events during treatment were similar in both groups. The responses seen in patients with KHE with KMP were profound and encouraging, suggesting that sirolimus plus prednisolone should be considered a valid treatment of KHE with KMP. This trial was registered at www.clinicaltrials.gov as #NCT03188068.

来源:Blood,查看原文。版权归原作者所有。

引用

  1. Ji Y, Chen S, Zhou J, et al. Sirolimus plus prednisolone vs sirolimus monotherapy for kaposiform hemangioendothelioma: a randomized clinical trial. Blood. 2022. PMID: 35030255. doi:10.1182/blood.2021014027

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。